Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma

✍ Scribed by Yasutsugu Takada; Mikiko Ueda; Takashi Ito; Seisuke Sakamoto; Hironori Haga; Yoji Maetani; Kohei Ogawa; Mureo Kasahara; Fumitaka Oike; Hiroto Egawa; Koichi Tanaka

• Publisher: John Wiley and Sons
• Year: 2006
• Tongue: English
• Weight: 220 KB
• Volume: 12
• Category: Article
• ISSN: 1527-6465
• DOI: 10.1002/lt.20642

✦ Synopsis

Living donor liver transplantation (LDLT) has evolved to represent an important surgical strategy for patients with hepatocellular carcinoma (HCC). However, due to disadvantages, including donor risks and higher rates of perioperative complications, LDLT has been considered as a second-line treatment in Japan. The present study retrospectively evaluated clinical outcomes for 93 patients with HCC who underwent LDLT at our institute, including 44 patients who exceeded Milan criteria (MC). A total of 73 patients (78%) displayed a history of previous treatment for HCC using various nontransplant methods. Median follow-up was 24 months (range, 1-76 months). At 4 years after LDLT, overall patient survival rate was 64%, with similar rates for within-MC and over-MC groups (68% vs. 59%, respectively; P ‫؍‬ 0.6548). However, cumulative recurrence rate was significantly higher in the over-MC group than in the within-MC group (35% vs. 15%, P ‫؍‬ 0.0190). Regarding history of conventional treatment for HCC before LDLT, patients who had received only 1-2 previous treatments showed significantly lower recurrence rates than patients with >3 treatments (9% vs. 37%, P ‫؍‬ 0.0411). In conclusion, LDLT may constitute an optional treatment with a chance of cure for patients with otherwise uncontrolled disease. However, repeated nontransplant treatments for recurrent HCC prior to LDLT may increase the risk of recurrence and impair the survival advantages conferred by LDLT. Liver